Eurofins BioPharma Product Testing Capacity Update April 2025: Analytical Services

Viral contaminants can be introduced throughout the complex biopharmaceutical manufacturing process via any number of mechanisms, including raw materials, cell banks, and manufacturing personnel. Accurate, timely Unprocessed Bulk (UPB)/Bulk harvest testing is critical not only to product safety, but also to prevent contamination of downstream processing equipment which results in lengthy and costly decontamination procedures and critical product shortages. Streamline your product development by partnering with a vendor that offers integrated testing services at a single location. This approach ensures continuous support throughout the product lifecycle and provides flexible testing solutions to address the growing complexity and diversity of biologics products.

During this presentation, we will dive into:

• Unprocessed Bulk Testing Requirements, Viral Assays & non-traditional methods, including Next Generation Sequencing (NGS)
• Transmission Electron Microscopy (TEM) testing of Unprocessed Bulk via improved thin-sectioning method